Eli Lilly and Company (NYSE:LLY) Price Target Increased to $1,100.00 by Analysts at JPMorgan Chase & Co.

Eli Lilly and Company (NYSE:LLY) had its target price lifted by JPMorgan Chase & Co. from $1,050.00 to $1,100.00 in a report released on Friday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other analysts also recently commented on the stock. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a buy rating in a research report on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a hold rating in a research report on Thursday, September 5th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an overweight rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a hold rating to a buy rating and boosted their price target for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, Truist Financial restated a buy rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $977.35.

Eli Lilly and Company Trading Down 1.2 %

Shares of NYSE:LLY opened at $923.71 on Friday. The company has a market cap of $877.92 billion, a PE ratio of 136.04, a P/E/G ratio of 2.79 and a beta of 0.42. The company’s 50-day moving average price is $897.12 and its 200 day moving average price is $832.88. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 646,878 shares of company stock valued at $591,465,138 over the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. grew its position in Eli Lilly and Company by 18.4% during the second quarter. Newbridge Financial Services Group Inc. now owns 3,850 shares of the company’s stock valued at $3,486,000 after purchasing an additional 597 shares in the last quarter. Cannon Financial Strategists Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $315,000. Heritage Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $9,582,000. Lazari Capital Management Inc. lifted its stake in Eli Lilly and Company by 59.0% in the second quarter. Lazari Capital Management Inc. now owns 477 shares of the company’s stock valued at $432,000 after acquiring an additional 177 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $205,136,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.